1. Neues zur Therapie mit Cannabinoiden.
- Author
-
Karsch-Völk, Marlies and Heim, Thomas M.
- Subjects
- *
MEDICAL marijuana , *MEDICAL care , *EVIDENCE-based medicine , *RANDOMIZED controlled trials , *CHRONIC pain - Abstract
Background: The "Cannabis as Medicine" Act (Gesetz "Cannabis als Medizin") has permitted the medical use of cannabis preparations under certain conditions since March 2017. It does not specify certain restrictive indications. Since its inception, the volume of prescriptions for cannabinoid-containing drugs skyrocketed. Whether this reflects an actual improvement in health care is controversial. Search method: This text is based on the clinical article "Cannabinoid-containing medicines" in Deximed (www.deximed.de), an online handbook for family physicians (FPs). For this article, sources, identified by selective literature research, were taken into account, including publications of the German Drug Commission, the comprehensive narrative review "Cannabis-Report" and available guidelines. Main Messages: Only in a few indications medical effectiveness of cannabis preparations has been proven, and only few finished medical products are available. In most cases, the prescription is a nolabel use. The most common prescription indication is chronic pain. The volume of prescriptions and associated costs are high despite poor evidence base. The highest costs are caused by the prescription of cannabis flowers and preparations thereof. About half of the costs arise from prescriptions by general practitioners. Conclusions: The prescription rates show that cannabinoid treatment is seen as a GP task. In order to proceed in an evidence-based and well-informed manner, sufficiently large randomized controlled trials, comprehensive early assessments by the Federal Joint Committee (Gemeinsamer Bundesausschuss), and more precise legal requirements and restrictions on use are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF